Top Back to top

Complications and Quality of Life Working Party survey of the use of busulfan in the conditioning for allogeneic hematopoietic cell transplantation in adults

We would like to invite you to participate in a survey about the ways busulfan is used in the conditioning for hematopoietic cell transplantation (HCT). The background for this initiative is the following: Busulfan-based regimens are widely used as conditioning for allogeneic HCT, and including all variants they are at present the most commonly used conditioning regimens. The policy of the use of busulfan has changed greatly over the years. From the traditional oral administration divided in four daily doses, many centers moved to the use of targeted dosing based on pharmacokinetic analysis, and more recently the use of the intravenous formulation of the drug has been broadly adopted, initially dividing the administration in four daily doses as for the oral formulation and subsequently moving to fewer doses, often once daily only. Also, lower doses than the traditional oral 16 mg/kg or the equivalent i.v. dose are now widely used in reduced intensity or reduced toxicity conditioning regimens. For these reasons the use of busulfan is at the moment heterogenic and there is no standard practice. One of the commissions of the EBMT is to standardize practices in stem cell transplantation, and the present survey would serve this purpose. Based on the results of this survey and the data available from the literature, the aim is to produce a statement of the current practice and recommendations for a standardized policy in the use of busulfan.

Study number:
Type of transplant:
Short title:
Study status:
Deadline for data collection:
Study design:
Primary objective:
Key inclusion criteria:
Principal investigator:
Tapani Ruutu
Principal investigator email:
EBMT Study coordinator:
Steffie van der Werf, Nelleke van ‘t Veer
Study coordinator email: